JPMorgan Chase & Co. restated their underweight rating on shares of Qiagen (NYSE:QGEN) in a research report report published on Tuesday morning, BenzingaRatingsTable reports. JPMorgan Chase & Co. currently has a price objective on the stock, down from their prior price objective of .
QGEN has been the subject of several other reports. DZ Bank reaffirmed a neutral rating on shares of Qiagen in a report on Wednesday, July 24th. ValuEngine downgraded Qiagen from a buy rating to a hold rating in a report on Tuesday, August 20th. Barclays increased their price target on Qiagen from $43.00 to $45.00 and gave the stock an overweight rating in a report on Friday, June 21st. Deutsche Bank reaffirmed a buy rating on shares of Qiagen in a report on Friday, July 26th. Finally, Goldman Sachs Group reaffirmed a buy rating on shares of Qiagen in a report on Thursday, August 1st. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. Qiagen has a consensus rating of Hold and a consensus target price of $35.25.
Shares of QGEN opened at $27.08 on Tuesday. The company has a current ratio of 1.77, a quick ratio of 1.59 and a debt-to-equity ratio of 0.54. The firm has a market cap of $5.73 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 1.69 and a beta of 0.85. The company’s 50 day simple moving average is $33.11 and its 200-day simple moving average is $37.36. Qiagen has a 12-month low of $25.04 and a 12-month high of $41.55.
Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, July 24th. The company reported $0.33 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.34 by ($0.01). Qiagen had a return on equity of 12.10% and a net margin of 12.94%. The business had revenue of $381.60 million for the quarter, compared to analysts’ expectations of $386.37 million. During the same quarter last year, the business posted $0.33 earnings per share. The business’s revenue was up 1.2% on a year-over-year basis. As a group, equities research analysts forecast that Qiagen will post 1.39 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in QGEN. Private Capital Group LLC lifted its holdings in Qiagen by 354.0% in the second quarter. Private Capital Group LLC now owns 681 shares of the company’s stock valued at $25,000 after acquiring an additional 531 shares during the period. O Shaughnessy Asset Management LLC acquired a new stake in Qiagen in the first quarter valued at $30,000. Tower Research Capital LLC TRC lifted its holdings in Qiagen by 1,244.7% in the second quarter. Tower Research Capital LLC TRC now owns 1,385 shares of the company’s stock valued at $56,000 after acquiring an additional 1,282 shares during the period. Bessemer Group Inc. lifted its holdings in Qiagen by 5,918.5% in the second quarter. Bessemer Group Inc. now owns 1,625 shares of the company’s stock valued at $66,000 after acquiring an additional 1,598 shares during the period. Finally, Rockefeller Capital Management L.P. lifted its holdings in Qiagen by 83.1% in the first quarter. Rockefeller Capital Management L.P. now owns 2,113 shares of the company’s stock valued at $86,000 after acquiring an additional 959 shares during the period. 62.10% of the stock is owned by institutional investors.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.